The interaction between chronic oral slow-release theophylline and single-dose intravenous erythromycin. 1987

J Pasic, and S H Jackson, and A Johnston, and C A Peverel-Cooper, and P Turner, and K Downey, and D M Chaput de Saintonge

Eight volunteers were each given 300 mg of erythromycin lactobionate by i.v. infusion over 15 min in the presence and absence of chronic dosing with slow-release theophylline. Pharmacokinetic profiles were obtained for theophylline in the presence and absence of erythromycin and for erythromycin in the presence and absence of theophylline. A very small, clinically unimportant, but statistically significant increase occurred in mean (+/- S.E.M.) serum theophylline concentration from 4.9 +/- 0.3 mg/l to 5.2 +/- 0.3 mg/l in the presence of erythromycin (P = less than 0.01). The theophylline pharmacokinetic parameters did not change significantly. The only changes in erythromycin pharmacokinetics were an increase in the renal excretion (0-12 h) from 5.5 +/- 4.0 mg to 11.2 +/- 6.0 mg (P less than 0.03) and an increase in renal clearance (0-2 h) from 9.0 +/- 6.0 ml/min to 21.6 +/- 15 ml/min (P less than 0.05) in the presence of theophylline.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses

Related Publications

J Pasic, and S H Jackson, and A Johnston, and C A Peverel-Cooper, and P Turner, and K Downey, and D M Chaput de Saintonge
April 1986, British journal of clinical pharmacology,
J Pasic, and S H Jackson, and A Johnston, and C A Peverel-Cooper, and P Turner, and K Downey, and D M Chaput de Saintonge
February 1978, Pediatrics,
J Pasic, and S H Jackson, and A Johnston, and C A Peverel-Cooper, and P Turner, and K Downey, and D M Chaput de Saintonge
October 1982, British journal of clinical pharmacology,
J Pasic, and S H Jackson, and A Johnston, and C A Peverel-Cooper, and P Turner, and K Downey, and D M Chaput de Saintonge
February 1982, British journal of clinical pharmacology,
J Pasic, and S H Jackson, and A Johnston, and C A Peverel-Cooper, and P Turner, and K Downey, and D M Chaput de Saintonge
June 1996, Asian Pacific journal of allergy and immunology,
J Pasic, and S H Jackson, and A Johnston, and C A Peverel-Cooper, and P Turner, and K Downey, and D M Chaput de Saintonge
January 1988, The Journal of asthma : official journal of the Association for the Care of Asthma,
J Pasic, and S H Jackson, and A Johnston, and C A Peverel-Cooper, and P Turner, and K Downey, and D M Chaput de Saintonge
September 1983, Chest,
J Pasic, and S H Jackson, and A Johnston, and C A Peverel-Cooper, and P Turner, and K Downey, and D M Chaput de Saintonge
September 1981, British journal of clinical pharmacology,
J Pasic, and S H Jackson, and A Johnston, and C A Peverel-Cooper, and P Turner, and K Downey, and D M Chaput de Saintonge
January 1992, Veterinary research communications,
J Pasic, and S H Jackson, and A Johnston, and C A Peverel-Cooper, and P Turner, and K Downey, and D M Chaput de Saintonge
January 1984, European journal of clinical pharmacology,
Copied contents to your clipboard!